[{"id":"cb3cb1db-2e3e-4730-8a0c-9a0d27e26ede","acronym":"","url":"https://clinicaltrials.gov/study/NCT06471673","created_at":"2025-02-26T10:47:22.224Z","updated_at":"2025-02-26T10:47:22.224Z","phase":"Phase 1/2","brief_title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","source_id_and_acronym":"NCT06471673","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" PD-L1 • PD-L2 • PRAME","pipe":"","alterations":" ","tags":["PD-L1 • PD-L2 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Bria-OTS"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/29/2024","start_date":" 05/29/2024","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-08-26"}]